ResearcherHenan University of Chinese MedicineActive in the last 2 years

Huahui Zeng

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5102407706. Sources: OpenAlex.

Their work

Papers: 5 (first author 1, last author 3)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 8

Papers, trials and grants by year

2022: 3 papers · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 5

Smart-responsive lentinan-DMXAA conjugate for synergistic STING-mediated pancreatic cancer immunotherapy. Last author DOI 10.1016/j.ijpharm.2026.126996 ↗
Lycium barbarum Polysaccharide-Stabilized Selenium Nanoparticles Deliver Triptolide to Induce Apoptosis for Pancreatic Cancer In Vitro and In Vivo. Last author DOI 10.1021/acsomega.4c04743 ↗
Celastrol-conjugated chitosan oligosaccharide for the treatment of pancreatic cancer. Last author DOI 10.1080/10717544.2021.2018521 ↗
A mitochondria-targeted nano-platform for pancreatic cancer therapy. Co-author DOI 10.3389/fchem.2022.951434 ↗
TP-CSO: A Triptolide Prodrug for Pancreatic Cancer Treatment. First author DOI 10.3390/molecules27123686 ↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Xiangxiang Wu · 4 shared papers, 2022–2026 · strength 0.75
Zhenqiang Zhang · 2 shared papers, 2022–2025 · strength 0.41
- Paper Lycium barbarum Polysaccharide-Stabilized Selenium Nanoparticles Deliver Triptolide to Induce Apoptosis for Pancreatic … DOI 10.1021/acsomega.4c04743 ↗
- Paper Celastrol-conjugated chitosan oligosaccharide for the treatment of pancreatic cancer. DOI 10.1080/10717544.2021.2018521 ↗
Zhengxian Zhang · 1 shared paper, 2026 · strength 0.32
- Paper Smart-responsive lentinan-DMXAA conjugate for synergistic STING-mediated pancreatic cancer immunotherapy. DOI 10.1016/j.ijpharm.2026.126996 ↗
Jiaxing Wang · 1 shared paper, 2026 · strength 0.32
- Paper Smart-responsive lentinan-DMXAA conjugate for synergistic STING-mediated pancreatic cancer immunotherapy. DOI 10.1016/j.ijpharm.2026.126996 ↗
Xiaoke Tan · 2 shared papers, 2022 · strength 0.29
- Paper Celastrol-conjugated chitosan oligosaccharide for the treatment of pancreatic cancer. DOI 10.1080/10717544.2021.2018521 ↗
- Paper A mitochondria-targeted nano-platform for pancreatic cancer therapy. DOI 10.3389/fchem.2022.951434 ↗
Xiaofang Li · 1 shared paper, 2025 · strength 0.27
- Paper Lycium barbarum Polysaccharide-Stabilized Selenium Nanoparticles Deliver Triptolide to Induce Apoptosis for Pancreatic … DOI 10.1021/acsomega.4c04743 ↗
Xinlong Wang · 1 shared paper, 2022 · strength 0.15
- Paper TP-CSO: A Triptolide Prodrug for Pancreatic Cancer Treatment. DOI 10.3390/molecules27123686 ↗
Xiaohu Zeng · 1 shared paper, 2022 · strength 0.15
- Paper Celastrol-conjugated chitosan oligosaccharide for the treatment of pancreatic cancer. DOI 10.1080/10717544.2021.2018521 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.